Business Operation · 2025
In this section22 topics
- Corporate Information4 items
- Dividend Policy2 items
- Major Shareholders1 item
- Business Strategies Overview5 items
- Material Changes & Developments1 item
- Use of Proceeds from Securities Offerings1 item
- Commitments Made in the Registration Statement1 item
- Group Operating-Structure Policy1 item
- Companies Where the Company Holds ≥10%1 item
- Shareholders with Potential Conflict of Interest1 item
- Relationships Among Major Shareholders1 item
- Shareholders' Agreement1 item
- Shareholding Diagram (Group Structure)3 items
- Income Structure3 items
- Product / Service Characteristics2 items
- Research & Development6 items
- Assets Used in the Business6 items
- Marketing Policy & Competition3 items
- Procurement of Products & Services8 items
- Projects Under Construction7 items
- Debentures & Bills of Exchange1 item
- Convertible Securities1 item
Corporate Information
Company Name
Specialty Natural Products Public Company Limited
Telephone
0-3845-8698
Website
www.snpspcl.com
secretary@snpthai.com
Dividend Policy
Dividend Policy
The Board of Directors may consider the payment of annual dividends of the Company, subject to approval by the shareholders’ meeting, except for interim dividends which the Board of Directors has the authority to approve from time to time when the Company has sufficient profits to do so, and shall report such payment to the shareholders’ meeting at the next meeting.
The Company has a policy to pay dividends to shareholders at a rate of not less than 30% of net profit from the separate financial statements after deduction of corporate income tax and all statutory reserves as prescribed by law and the Company’s Articles of Association, provided that the Company has no accumulated losses. The Board of Directors shall consider dividend payments taking into account various factors for the benefit of shareholders, such as economic conditions, operating results and financial position of the Company, cash flows of the Company, annual investment plans of the Company, the necessity of capital for future business expansion, reserves for loan repayment or working capital within the Company, conditions and restrictions under loan agreements, and that the dividend payment shall not have a material adverse impact on the normal operations of the Company, as necessary, appropriate, and as the Board of Directors deems fit.
Historical Dividend Payments
| This Year | Last Year | 2 Years Ago | 3 Years Ago | Metric | Description |
|---|---|---|---|---|---|
| 0.28 | 0.26 | 0.12 | 0.42 | Net profit per share (Baht : Share) | Net profit per share (baht : share) |
| 0.2 | 0.29 | 0 | 1.75 | Dividend per share (Baht : Share) | Dividend per share (baht : share) |
| 0 | 0 | 0 | 0 | Dividend stock ratio (Number of original shares: dividend shares) | Ratio of stock dividend payment (existing share : stock dividend) |
| 0 | 0 | 0 | 0 | Dividend share value per share (Baht : Share) | Value of stock dividend per share (baht : share) |
| 0.2 | 0.29 | 0 | 1.75 | Total dividend payment value (Baht : Share) | Total dividend payment (baht : share) |
| 7.4 | 111.62 | 0 | 420.26 | Dividend payout ratio to net profit (%) | Dividend payout ratio compared to net profit (%) |
Business Strategies Overview
Chairman's Message
Over the past several years, Specialty Natural Products Public Company Limited (“SNPS” or the “Company”) has continuously developed and deepened its expertise in Thai botanicals and natural resources, establishing itself as an integral part of the global health and beauty industry supply chain, amidst rapidly evolving economic conditions, technological advances, and rising stakeholder expectations.
The Board of Directors recognizes the importance of establishing clear, prudent, and adaptable strategic direction for long-term success. Accordingly, the Board has endorsed a strategic framework for the period 2026–2028, focusing on quality-driven growth, enhanced competitiveness, and responsible business operations with due regard for society and the environment.
The Company’s strategy is anchored in the principle of elevating Thai botanicals to international standards through its 4C innovation framework: developing raw materials from upstream sources (Cultivation), generating innovation and knowledge through research (Creation), transforming outputs into value-added products and solutions (Conversion), and sharing value with stakeholders throughout the value chain (Contribution).
Under the 2026–2028 strategic plan, the Company’s priorities include expanding into international markets and increasing the share of export revenue, enhancing operational efficiency and profitability, generating revenue from innovation and intellectual property, and embedding Environmental, Social, and Governance (ESG) considerations into policy-making and business decisions at all levels.
The Board of Directors firmly believes that sustainable growth cannot be achieved through short-term performance alone; it requires a foundation of sound corporate governance, prudent risk management, continuous human capital development, and value co-creation with farmers, business partners, communities, and all stakeholders.
On behalf of the Board of Directors, I would like to express our sincere gratitude to shareholders, customers, business partners, employees, and all stakeholders for their continued support and trust in the Company. The Board remains committed to overseeing and supporting management in achieving the Company’s strategic objectives and delivering stable, transparent, and sustainable long-term growth.
Vision
“We are committed to setting new standards for regional botanicals on the global stage, to sustain human health and planetary well-being.”
The Company is dedicated to elevating regional botanicals and natural resources to international standards through research, development, and sourcing of natural ingredients supported by scientific evidence, in service of the health and beauty industry and human well-being, coupled with responsible resource utilization and environmental stewardship.
The Company aspires to be a leading developer and supplier of natural ingredients in the Asian region, operating under the principles of ethics, transparency, and good corporate governance to deliver appropriate and sustainable returns for shareholders while maintaining a balanced responsibility toward society, the environment, and all stakeholders.
Objectives
“Partnering with Nature, Empowering Growth”
Achieve continuous and stable growth in operating results based on an efficient business structure capable of long-term competitiveness, and support the commercialization of local wisdom to create sustainable economic value.
Develop high-value-added natural products and innovations by integrating local wisdom with scientific research and technology to elevate Thai botanicals and natural resources to international standards.
Conduct business with integrity, transparency, and good governance, respecting the rights of shareholders, customers, business partners, employees, and all stakeholder groups, to build confidence and sustainability in long-term operations.
Minimize environmental impact and promote efficient resource utilization throughout the value chain—from raw material sourcing and manufacturing to product delivery—to support balanced growth across economic, social, and environmental dimensions.
Strengthen organizational capabilities to adapt to changes in the business environment, regulations, technology, and market expectations, in support of growth in an increasingly sustainable and responsible global economy.
Goals
The Company operates under its proprietary 4C framework—Cultivation, Creation, Conversion, and Contribution—a value creation model spanning the entire business chain from upstream to midstream to downstream. This framework is designed to elevate Thai botanicals and natural resources to international standards through research, development, and innovation supported by scientific evidence, in conjunction with responsible business practices toward society, the environment, and all stakeholders.
1. Cultivation (Develop)
Develop quality raw materials from upstream by collaborating with farmers and community networks to upgrade herbal cultivation processes to meet appropriate quality, consistency, and certification standards, thereby securing stable raw material sources and reducing long-term supply chain risks.
2. Creation (Innovate)
Develop innovative herbal extracts and active ingredients through research, science, and technology, in collaboration with research institutions and partners both domestically and internationally, to enhance product quality, efficacy, and compliance with international standards.
3. Conversion (Commercialize)
Transform developed knowledge and extracts into value-added products, both as ingredients for customers and as finished products under the Company’s own brands, to expand business opportunities and access domestic and international markets effectively.
4. Contribution (Create Shared Value)
Create shared value for all stakeholders through knowledge dissemination, capacity building for farmers and communities, efficient resource utilization, and ethical business practices, to support sustainable growth at both the organizational and societal levels.
Business Strategies
The Company has formulated its business strategies for the period 2026–2028 to support sustainable growth, enhanced competitiveness, and long-term value creation for shareholders and stakeholders. The strategy is organized around four pillars:
Strategy 1: Global Market Leadership and Export Expansion
The Company aims to strengthen its position in international markets by broadening its customer base and progressively increasing the share of export revenue, while enhancing the reputation and competitiveness of its natural ingredient products to become a leading natural ingredient supplier in Southeast Asia.
Key implementation approaches:
Develop products aligned with international standards and customer requirements.
Expand collaboration with international business partners and distributors.
Increase the share of export revenue and diversify geographic market exposure.
Strategy 2: Operational Excellence and Profitability Enhancement
The Company aims to enhance operational efficiency throughout the value chain—from raw material sourcing and manufacturing to product delivery—with emphasis on shifting the product portfolio toward higher-margin categories and improving resource utilization efficiency to reduce costs and increase profitability.
Key implementation approaches:
Increase the share of premium herbal products and direct material (DM) solutions in the revenue mix.
Improve production process efficiency and eliminate hidden costs.
Manage and control expense growth in alignment with sustainable EBITDA growth targets.
Add value to domestically sourced raw materials to meet international market demand.
Strategy 3: Innovation Ecosystem and IP Monetization
The Company aims to generate growth through innovation and knowledge by systematically developing and managing intellectual property to create new revenue streams and enhance long-term competitiveness.
Key implementation approaches:
Establish and develop the Company’s innovation ecosystem.
Develop new formulations and technologies eligible for patent protection and commercial application.
Generate revenue from licensing, co-development, and technology transfer arrangements.
Bridge research outputs from domestic and international institutions to commercial deployment.
Strategy 4: ESG Leadership and Regenerative Impact
The Company embeds Environmental, Social, and Governance (ESG) considerations into strategic planning and business decision-making at all levels, with the aim of reducing environmental impact, strengthening farming communities, and elevating corporate governance standards to internationally recognized benchmarks.
Key implementation approaches:
Increase the use of renewable energy and reduce greenhouse gas (GHG) emissions in Scope 1 and Scope 2.
Develop and implement science-based carbon reduction plans for Scope 3 emissions.
Expand the herbal farmer network and promote responsible agricultural practices.
Establish and maintain ESG ratings at appropriate levels according to international benchmarks.
The 2026–2028 business strategies are designed to achieve a balanced approach across economic growth, competitiveness, innovation, and sustainability, enabling the Company to grow steadily over the long term and create enduring value for shareholders and all stakeholders.
Material Changes & Developments
Material Changes & Developments
| Year | Description |
|---|---|
| 1,999 |
|
| 2,000 |
|
| 2,001 |
|
| 2,002 |
|
| 2,003 |
|
| 2,007 |
|
| 2,009 |
|
| 2,012 |
|
| 2,013 |
|
| 2,016 |
|
| 2,017 |
|
| 2,018 |
|
| 2,019 |
|
| 2,020 |
|
| 2,021 |
|
| 2,022 |
|
| 2,023 |
|
| 2,024 |
|
| 2,025 |
|
Use of Proceeds from Securities Offerings
Is There Money Raised from a Securities Offering Still to Report On?
No
Commitments Made in the Registration Statement
Are There Commitments or Conditions from an Offering or Listing?
No
Group Operating-Structure Policy
Description
The Company has established a division of operations among Group companies in accordance with the objectives of each company’s incorporation, as detailed below:
1. Specialty Innovation Co., Ltd. (“SI”)
SI was incorporated on 16 February 2012 with a registered capital of THB 1 million, divided into 10,000 ordinary shares with a par value of THB 100 per share. SI has increased its capital on a continuous basis, and as of 2022, SI has a registered capital of THB 140 million, divided into 1,400,000 ordinary shares with a par value of THB 100 per share. The Company holds 99.53% of SI’s total issued and paid-up shares, with the remaining 0.47% held by SNI. SI engages in the manufacturing and distribution of health, beauty, and hygiene products, comprising cosmetics and cosmeceuticals, dietary supplements, herbal products, and medical products, in both the contract development and manufacturing of products under customers’ brands (Original Design Manufacturer: ODM) and the manufacturing and distribution of products under the Group’s brands (Original Brand Manufacturer: OBM).
2. Kanae Innovation Co., Ltd. (“KI”)
KI was incorporated on 7 November 2018 by the Krisdaphong family with a registered capital of THB 1 million, divided into 100,000 ordinary shares with a par value of THB 10 per share. In June 2024, KI increased its registered capital by THB 5 million, bringing the total registered capital to THB 40 million. The Company holds 80.00% of KI’s total issued and paid-up shares. KI engages in the distribution of biomass-based foil sachets, as a joint venture with Kanae Company Limited, a full-service packaging manufacturer and distributor in Japan. Kanae Company Limited will disclose and transfer knowledge of COSMOPACK technology by providing technical assistance and will procure COSMOPACK filling machines for KI. In addition, Kanae Company Limited and Approved Packaging Suppliers will supply packaging raw materials to KI at agreed prices.
3. Wellnovations Co., Ltd. (“WELL”)
WELL was incorporated on 28 April 2021 by the Kritsadapong family. Currently, WELL has a registered capital of THB 66,663,000, divided into 6,666,300 ordinary shares with a par value of THB 10 per share. The Company holds 52.50% of WELL’s total issued and paid-up shares.
WELL engages in the distribution of herbal innovation products under the Group’s trademarks, with its main products being the Complete Formula Closure (Colosure) dietary supplement under the Wellnova brand. The joint venture in WELL has the objective of generating growth and serving as a platform for bringing research outputs of research agencies and partners to commercial markets. Each joint venture partner has agreed to support the following:
SNPS shall be responsible for product manufacturing and distribution, business administration, facilitation of product development, and related services.
NSTDA shall facilitate the linkage of research and development and related support services of the National Science and Technology Development Agency.
The Harnpanich group shall support product sales, particularly the distribution of products through hospital channels.
Companies Where the Company Holds ≥10%
Companies (≥10% Holding)
| Company Name | Address | Province | Zip Code | Telephone | Business Type | Security Type | Shares | Paid-up Shares |
|---|---|---|---|---|---|---|---|---|
| Specialty Innovation Co., Ltd. | 9 Moo 21, Bang Phli Yai Subdistrict, Bang Phli District | Samut Prakarn | 10540 | 023-133456 | SI Manufacturing and distribution of health, beauty, and hygiene products | Common shares | 1,400,000 | 140,000,000 |
| Kanae Innovation Co., Ltd. | 9 Moo 21, Bang Phli Yai Subdistrict, Bang Phli District | Samut Prakarn | 10540 | 023-133456 | Distribution of biomass-based foil sachet packaging; JV with Kanae Company Limited, Japan | Common shares | 4,000,000 | 40,000,000 |
| Wellnovations Co., Ltd. | 9 Moo 21, Bang Phli Yai Subdistrict, Bang Phli District | Samut Prakarn | 10540 | 023-133456 | Distribution of herbal innovation products under the Group’s trademarks; main product: Complete Formula Closure (Colosure) under Wellnova brand | Common shares | 6,666,300 | 66,663,000 |
| L-Sola 3 Co., Ltd. | 102 Na Ranong Road, Khlong Toei, | 10110 | 023-133456 | Electricity generation and transmission | Common shares | 10,000,000 | 10,000,000 |
Income Structure
Product / Service Income
| Category | Description | This Year | This Year % | Last Year | Last Year % | 2 Years Ago | 2 Years Ago % |
|---|---|---|---|---|---|---|---|
| Total revenue from operations | Total revenue from operations | 571,702.91 | 100 | 474,673.51 | 100 | 368,090.87 | 100 |
| Revenue from sales | 542,742.34 | 94.93 | 450,560.41 | 94.92 | 353,587.34 | 96.06 | |
| Revenue from services | 11,467.87 | 2.01 | 6,745.99 | 1.42 | 3,114.67 | 0.85 | |
| Other | Others | 17,492.7 | 3.06 | 17,367.11 | 3.66 | 11,388.86 | 3.09 |
Export Income
| Category | Description | This Year | This Year % | Last Year | Last Year % | 2 Years Ago | 2 Years Ago % |
|---|---|---|---|---|---|---|---|
| Total revenue | Total revenue | 571,702.91 | 100 | 474,673.51 | 100 | 368,090.87 | 100 |
| Domestic | Domestic | 525,905.02 | 91.99 | 420,913.65 | 88.67 | 331,272 | 90 |
| International | International | 28,305.19 | 4.95 | 36,892.76 | 7.77 | 36,818.87 | 10 |
Other Income
| Operating Other Income | Non-Operating Other Income | Share of Profit |
|---|---|---|
| 1710 · As of year: 17492.7 · Description: Total other income · As of yesteryear: 17367.1 · As of year before yesteryear: 11388.86 · 1711 · As of year: 17492.7 · Description: Other income from operations · As of yesteryear: 17367.1 · As of year before yesteryear: 11388.86 | 1712 · As of year: 0.0 · Description: Other income not from operations · As of yesteryear: 0.0 · As of year before yesteryear: 0.0 | 1713 · As of year: 160.51 · Description: Share of profit · As of yesteryear: 153.81 · As of year before yesteryear: 210.93 |
Product / Service Characteristics
Business Type
3114
Business Groups
| Business Group | Description |
|---|---|
| Standardized Herbal Extract Business (API) | The SNPS Group (“the Company”) manufactures and distributes standardized herbal extracts (Active Phyto-Ingredients, or API) used as raw materials for the dietary supplement, food, cosmetics, and health product industries. Operations cover the entire value chain from sourcing quality herbal raw materials from certified cultivation sources, extraction, quality control, through to product development tailored to specific customer requirements. The Company has deep expertise in Thai botanicals developed over more than 25 years, focusing on producing extracts with consistent quality, safety, and efficacy. This is achieved through scientific knowledge, advanced extraction technology, and quality control systems conforming to international standards, building confidence among domestic and international customers. The Company also emphasizes developing products aligned with long-term trends in health and sustainability. |
| Health, Beauty, and Hygiene Product Business | The Group manufactures and distributes health, beauty, and hygiene products through two main business lines: (a) Original Design Manufacturer (ODM): perated by Specialty Innovation Co., Ltd. (“SI”), the Company’s subsidiary, providing one-stop service for health, beauty, and hygiene products covering consultation, formula design and development, raw material selection, product registration, quality control, and industrial-scale manufacturing. As of end-2025, the Group had more than 1,500 ODM product SKUs in production covering dietary supplements, cosmetics, and healthcare products, with 280+ ready-to-use formulations. (b) Original Brand Manufacturer (OBM): perated by Wellnovations Co., Ltd. (“WELL”), focusing on developing and marketing differentiated, high-value health, beauty, and hygiene products based on deep R&D. Key products include the Colosure dietary supplement under the Wellnova brand. |
Research & Development
Has R&D Policy (Y/N)
Yes
R&D Cost — Description
The majority of R&D expenditure comprises personnel-related costs, accounting for over 60% each year. The remainder consists of other expenses, including analytical testing and inspection fees, equipment depreciation, and various research-related consumables.
With a vision to continuously and sustainably advance technology and innovation, the Company places importance on investment in research and development (R&D) as a critical mechanism for strengthening competitiveness and supporting long-term growth. Over the past 3 years, the Company has continuously allocated R&D budgets to serve as the foundation for driving innovation, developing products, and enhancing the ability to adapt to changes in the industry and market demands.
The Company conducts R&D investment under the following key approaches:
1. Innovation Development for Sustainable Growth
The Company collaborates with research institutions and leading universities to develop new technologies and products capable of meeting future market demands, with a focus on creating innovation-based differentiation and enhancing competitiveness, as well as developing the capabilities of the internal research team to support the Company’s long-term growth.
2. Efficient R&D Budget Management
The Company’s R&D investment is subject to planning, cost-benefit evaluation, and continuous performance monitoring processes to ensure that budgets are allocated to projects with commercial development potential and that can create added value for the organization efficiently.
3. Linking R&D with Corporate Growth Strategy
R&D expenditure is integrated with the Company’s business strategy, with a focus on developing core technology platforms that support market expansion both domestically and internationally, which strengthens competitiveness, maintains industry leadership, and supports continuous customer base expansion.
R&D Cost — Label
Research and development (R&D) expenses over the past 3 years (Million Baht)
R&D Cost — This Year
29930.66
R&D Cost — Last Year
23856.02
R&D Cost — 2 Years Ago
22002.07
Assets Used in the Business
Permanent Assets — Description
The Group has key fixed assets used in business operations, with a total net book value after accumulated depreciation, as shown in the consolidated financial statements as at 31 December 2025, totaling THB 226.10 million, with details as follows:
Permanent Assets — Appraisal
| Asset | Ownership | Obligation | Appraisal Value | Description |
|---|---|---|---|---|
| Land | Freehold | Mortgaged with commercial bank | 87,848,125 | Land and buildings NBV THB 162.24M (2025) and THB 168.92M (2024) pledged as collateral for secured credit facilities and bank guarantees |
| Buildings and improvements | Freehold | Mortgaged with commercial bank | 74,396,121 | Land and buildings NBV THB 162.24M (2025) and THB 168.92M (2024) pledged as collateral for secured credit facilities and bank guarantees |
| Machinery and factory equipment | Freehold | Mortgaged with commercial bank | 47,915,854 | Long-term loans fully repaid; currently in process of releasing machinery used as collateral |
| Factory tools and equipment | Freehold | No encumbrance | 4,210,686 | |
| Furniture, fixtures and office equipment | Freehold | No encumbrance | 6,247,535 | |
| Vehicles | Freehold | No encumbrance | 5,485,951 |
Intangible Assets — Description
The Group has intangible assets comprising computer software and research rights, with a total net book value after accumulated amortization per the consolidated financial statements as at 31 December 2025 of THB 5.52 million, with details as follows:
Intangible Assets — Appraisal
| Asset | Type | Appraisal Value |
|---|---|---|
| Computer software | Software | 5,200,156 |
| Research rights | Patent | 323,287 |
Has Subsidiaries Investment Policy (Y/N)
Yes
Subsidiaries Investment Policy — Description
The Company has a policy to invest in companies that are aligned with the Company’s objectives, vision, and growth strategy, which would result in increased operating results or profits for the Company, or to invest in businesses that create synergy for the Company, in order to enhance competitiveness and to enable the Company to achieve its objective of becoming a leading operator in its core business. The Company, its subsidiaries, and/or associates may consider making additional investments in other businesses to achieve attractive returns on investment. Investment decisions by the Company, its subsidiaries, and/or associates shall be subject to feasibility analysis, potential assessment, and investment risk evaluation through appropriate investment analysis procedures, which must be approved by the Executive Committee meeting and/or the Board of Directors’ meeting and/or the shareholders’ meeting (as the case may be). The approval of investments in subsidiaries and/or associates must comply with relevant laws, regulations, and announcements. In addition, the Company shall appoint its representatives to serve as directors and executives in subsidiaries and/or associates in proportion to at least its shareholding in such subsidiaries and/or associates, to oversee and ensure that the operations of subsidiaries and/or associates are aligned with the Company’s policies.
Marketing Policy & Competition
Reporting Mode
3117
Marketing Policy (Overall)
The Group operates under the vision “Partnering with Nature, Empowering Growth”, focusing on the development of Active Phyto-Innovation—innovative plant-based extracts—to create quality products that promote good health sustainably. The Group has established four core business strategies as follows:
1. Emphasis on Research and Development to Create Product Differentiation
The Group focuses on continuous research and development to create products that are distinctive and supported by scientific evidence, in order to build competitive advantages in the global market.
In 2025, the Company invested THB 29.93 million in R&D, an increase from THB 23.86 million in the previous year, or an increase of 25.46%, reflecting the Company’s commitment to innovation development and enhancement of long-term competitiveness.
In addition, the Company has carried out research collaborations with external agencies and leading research institutions, including:
The Thai Red Cross Society and King Chulalongkorn Memorial Hospital, for the development of SALYWA artificial saliva gel for cancer patients with dry mouth conditions, which has been registered as a petty patent and helps improve patients’ quality of life.
The National Science and Technology Development Agency (NSTDA), for the development of herbal products with high commercial potential.
The Faculty of Medicine Siriraj Hospital, Mahidol University (SICRES), to support clinical research and strengthen the scientific evidence base of herbal extract products.
In 2025, the Company developed the following key product innovations:
NaturBrill — natural color innovations from Thai plants, comprising Rose Red (roselle), Royal Blue (butterfly pea), and Yellow Sunrise (Cape jasmine), for the food and health beverage industry.
Nior BGF — anthocyanin extract from biotechnology-fermented black sticky rice, which can be used in the cosmetics and healthcare product industries.
2. Expanding the Customer Base to High-Growth Markets
The Group focuses on expanding into customer segments with high growth potential, including:
Medical partners and healthcare facilities (Medical Partners)
Preventive health and wellness products (Preventive Health & Wellness)
Food additives, particularly natural plant-based colors (Natural Food Additives)
The Company launched natural color products under the NATUREBRILL brand, developed from Thai plants, in response to the continuously growing global demand for natural colors in the food industry.
In addition, the Company participated continuously in major international trade shows and academic conferences, including Vitafoods Europe, ICI Indonesia, VIV Asia, Cosmoprof CBE ASEAN, Fi Asia Thailand, Vitafoods Asia, in-cosmetics Asia, NanoThailand, and Cosmoprof Asia, to build awareness in the global market and expand business partner networks.
Currently, the Company has commenced product distribution through partner networks and distributors in 10 countries: India, Indonesia, Malaysia, Vietnam, Singapore, Australia, New Zealand, Japan, France, and Taiwan.
3. Developing Commercially Ready Innovation Products
The Group places importance on developing Branded Ingredients and intellectual property (IP) supported by scientific evidence, to enable rapid commercialization in the form of Active Phyto-Ingredients and product formulations developed to meet international standards.
Key innovation products include:
BGold — nanotechnology-level Kaempferia parviflora (black ginger) extract with clinical studies demonstrating efficacy in skin cell protection and collagen stimulation.
Closure — a dietary supplement under the Wellnova brand that received the INTARG Gold Medal 2024 from Poland.
GuVnis Gold — a nanotechnology dietary supplement for holistic health, co-developed with the National Science and Technology Development Agency (NSTDA).
4. Sustainable Supply Chain Management
The Company places importance on developing the supply chain from upstream to downstream, to enable efficient herbal raw material management, reduce risks from seasonal fluctuations, and support the maintenance of the business’s gross profit margins.
In terms of sustainable development, the Company has obtained the following key certifications:
Carbon Footprint for Organization (CFO) in February 2025, reflecting its commitment to conducting business under ESG principles.
Green Industry Level 3 (Green System) certification from the Ministry of Industry.
In addition, the Company has implemented the “Thankhun Thai Farm” program to build a collaborative network with farmers across more than 15 provinces nationwide through a Partnership Farming system, which helps improve the quality of life of Thai farmers while securing a sustainable supply of herbal raw materials for the Company.
Industry & Competition (Overall)
The Group operates in three main industries that continue to exhibit sustained growth: the herbal and pharmaceutical product industry, the cosmetics industry, and the dietary supplement industry. All three industries are driven by structural factors that support long-term growth.
1. Herbal and Pharmaceutical Product Industry
Global Herbal Extract Market: The global herbal extract market was valued at approximately USD 48.90 billion in 2025 and is projected to grow to USD 103.55 billion by 2034, representing a compound annual growth rate (CAGR) of 8.69%.
Region | Market Share 2024 | Value 2024 (USD bn) | CAGR 2025–2034 |
Asia-Pacific | 53% | 22.99 | 8.81% |
Europe | 22% | 9.56 | 7.5% |
North America | 14% | 6.09 | 8.0% |
Latin America, Middle East and Africa | 11% | 4.78 | 7.2% |
Source: Industry Market Research
Structural Drivers: The Asia-Pacific region commands the highest market share and is expected to maintain its leadership due to its rich biodiversity and wide variety of herbal plant species. Key countries such as China, India, Japan, and South Korea have centuries-old traditions of herbal use and traditional medicine, along with advanced manufacturing capabilities for herbal extracts and raw materials for health products.
Thailand Situation: Thailand is considered a country with significant advantages and market opportunities arising from the natural product trend, given that Thailand has more than 1,800 herbal species that can be utilized for industrial applications.
Government Policies Supporting the Thai Herbal Industry
2nd National Herbal Action Plan (2023–2027)
The Cabinet approved the 2nd National Herbal Action Plan 2023–2027 on 31 January 2023, with the Department of Thai Traditional and Alternative Medicine as the lead agency. The Plan comprises 5 strategies linking development throughout the value chain from upstream, midstream, to downstream, with the following key outcome indicators:
Registered herbal products to increase by at least 10% by 2027
Herbal medicine prescriptions in the public health system to increase by at least 10%
At least 50 herbal medicines to be included in the National List of Essential Medicines
National List of Essential Herbal Medicines (2nd Edition), 2025
The National Drug System Development Committee announced the National List of Essential Herbal Medicines, 2nd Edition, 2025, on 12 March 2025, to drive and promote the use of herbal medicines in the healthcare system in a concrete manner. This List aims to enable Thai traditional medicine practitioners, applied Thai traditional medicine practitioners, and modern medicine physicians in hospitals to systematically prescribe herbal medicines, in order to strengthen the country’s pharmaceutical security.
The National Herbal Policy Committee approved an integrated plan to bring herbs into economic development, under the collaboration of 6 key ministries: the Ministry of Public Health, Ministry of Commerce, Ministry of Industry, Ministry of Agriculture and Cooperatives, Ministry of Interior, and the Ministry of Higher Education, Science, Research and Innovation. The plan aims to develop the herbal industry throughout the value chain in all dimensions, from cultivation and herbal raw material management, research and innovation development, processing and value addition, to marketing promotion and building Thai herbal brands in the international market. The meeting also approved a 3-year plan (2025–2027) to drive the development of the Thai herbal SME industry, to strengthen competitiveness in both domestic and international markets, together with the establishment of the Key Message “Think Wellness Think Thai Herb” as the unified direction for promoting Thai herbs and herbal products to the global market.
In terms of the global market context, data from Euromonitor International indicates that the global retail value of herbal products stood at USD 60,589.8 million in 2024, with a continuously growing trend projected to reach USD 78,395.6 million by 2029, pointing to significant trade opportunities and the potential for Thai herbal industry market expansion on the international stage.
2. Cosmetics Industry
In 2024, the global Clean Beauty market was valued at approximately USD 9.38 billion and is projected to expand to USD 49.46 billion by 2032, with a CAGR of 14.99%. This growth reflects rising consumer demand for products free from harmful chemicals, that are sustainable, and that use ethically sourced raw materials.
Product Category | Market Share 2024 | CAGR 2025–2032 | Key Drivers |
Skincare | 41.70% | 14.0% | Demand for natural anti-aging ingredients |
Hair Care | 25.50% | 15.2% | Sulfate-free and paraben-free formulations |
Color Cosmetics | 18.80% | 15.4% | Biotech innovation and social media |
Others | 14.00% | 12.0% | Oral care and fragrance products |
Source: Fortune Business Insights, Grand View Research 2024
Key Industry Trends
Consumers worldwide are increasingly aware of the health risks potentially arising from the use of chemicals in conventional cosmetics, which is the primary factor driving demand for safer product alternatives. In addition, stricter international regulations serve as a significant driving force, such as the European Union’s Green Claims Directive, which requires operators to provide verified evidence to substantiate environmental claims and is expected to take full effect by 2026, as well as the U.S. FDA’s Modernization of Cosmetics Regulation Act (MoCRA), which mandates manufacturers to report serious adverse events from product use. These regulatory measures result in companies with robust safety surveillance systems and transparency having a significant competitive advantage in the market.
3. Dietary Supplement Industry
Longevity and Preventive Wellness Market: The global Longevity and Preventive Wellness market was valued at approximately USD 5,827.5 billion in 2024 and is projected to grow to USD 8,505.0 billion by 2030, representing a CAGR of 6.5%, reflecting the shift in consumer behavior from treatment to prevention.
Market Segment | Value 2024 (USD bn) | Value 2034 (USD bn) | CAGR |
Longevity Supplements | 10.70 | 20.20 | 7.1% |
Anti-Aging Supplements | 4.47 | 6.99 | 7.89% |
Healthy Aging Supplements | 1.53 | 2.20 | 7.5% |
Longevity & Anti-Aging Drugs | 19.18 | 58.43 | 11.9% |
Source: Grand View Research, Precedence Research, Intent Market Research 2024–2025
Aging Society and Business Opportunities: According to the World Health Organization (WHO) and the United Nations, the global population is aging rapidly. By 2030, it is projected that 1 in 6 people worldwide will be aged 60 years or over. The population aged 60+ is expected to increase from 1,000 million in 2020 to 2,100 million by 2050. This demographic shift is occurring in both developed and emerging markets and is correlated with a higher prevalence of chronic diseases and increasing demand for health, nutrition, and elderly care.
For Thailand, the country entered an Aging Society in 2005, with the population aged 60 and over exceeding 1 in 10. Thailand subsequently entered a Complete-Aged Society in 2021, with the population aged 60 and over exceeding 20% of the total population. It is projected that Thailand will become a Super-Aged Society, with the population aged 60 and over exceeding 28%, by 2035.
Knowledgeable Consumer Trends: Modern consumers are increasingly knowledgeable about the aging process and focus on prevention rather than treatment, placing importance on products that are science-backed, clean, and free from contamination. SNPS is able to respond to these needs through its standardized herbal extracts and Branded Ingredients that have undergone research and clinical testing.
Competitive Advantages of the Group
1. Experience and Expertise: More than 25 years in the herbal extract industry, with a farmer network across 15+ provinces through the Thankhun Thai Farm program.
2. International Standard Certifications: ISO 9001:2015, ISO 22716:2007, FSSC 22000, GHPP (Good Herbal Processing Practice), ECOCERT COSMOS APPROVED, Thailand Trust Mark (T Mark), HALAL, and Carbon Footprint for Organization.
3. End-to-End Manufacturing Capability: From upstream to downstream, including 412 extract products and 1,500+ finished products, with 280+ ready-to-use formulations.
4. Awards and Recognition: Prime Minister’s Industry Award, INTARG Gold Medal, NRCT Special Award from the National Research Council of Thailand.
Note: Market data referenced from Fortune Business Insights, Grand View Research, Precedence Research, Intent Market Research, World Health Organization (WHO), Euromonitor
Procurement of Products & Services
Reporting Mode
3117
Procurement (Overall)
The Group places importance on the procurement of quality raw materials that meet appropriate standards, to support the production of plant-based extracts and health, beauty, and dietary supplement products. The Company selects capable raw material manufacturers and distributors that are able to deliver quality raw materials consistently, in compliance with the Company’s quality specifications and delivery timelines.
The Company has prepared an Approved Vendor List to serve as a mechanism for selecting and controlling the quality of raw material manufacturers and distributors. The Research and Development Department is responsible for inspecting and evaluating the quality of raw materials before approving a vendor. The Company reviews vendor performance evaluations every 6 months, taking into consideration the quality of raw materials, consistency of delivery, and delivery track record as the primary criteria.
In addition, the Quality Control Department conducts random inspections of raw materials upon every delivery, to ensure that all raw materials used in the production process conform to the standards specified by the Company. The Company maintains a policy of sourcing raw materials from at least 2 manufacturers or distributors for key raw materials, in order to reduce the risk of dependence on any single supplier. In the past year, the Group did not purchase raw materials from any single manufacturer or distributor exceeding 30% of total raw material procurement value.
1. Herbal Plants
Herbal plants are a key raw material in the Group’s herbal extract production, such as Kaempferia parviflora (black ginger), Ganoderma lucidum (reishi mushroom), Phyllanthus emblica (Indian gooseberry), and Terminalia chebula (chebulic myrobalan). The Company procures herbal plants primarily from domestic sources, selecting from groups of farmers and producers that are reliable and capable of delivering raw materials that meet the Company’s quality standards.
For herbal plants that are used in high volumes and have continuous market demand, the Company procures from its network of farmer partners and community enterprises that have maintained cooperative relationships for more than 10 years, with advance planning and reservation of raw material quantities aligned with the annual production and sales plans.
In addition, the Company has operated the “Thankhun Thai Farm” program since 2010 to support farmer networks and community enterprises across more than 15 provinces nationwide, including Chiang Mai, Lampang, Phitsanulok, Phetchabun, Nakhon Phanom, and Sa Kaew. The Company transfers knowledge in herbal cultivation, harvesting, and processing, to help upgrade the quality of raw materials and add value to Thai herbal plants, while also creating income and long-term stability for farming communities in a sustainable manner.
The herbal plants procured by the Company are mostly in the form of dried herbs, coarsely ground, finely ground, or cut into pieces, to suit the Company’s extract production processes.
2. Herbal Extracts
Herbal extracts are a key raw material used in the production of the Group’s health, beauty, and hygiene products, such as Kaempferia parviflora (black ginger) extract, Phyllanthus emblica (Indian gooseberry) extract, Aloe vera extract, and Centella asiatica (Gotu kola) extract.
The Company procures herbal extracts primarily from domestic manufacturers and distributors. In certain cases involving specialty herbs that the Company cannot extract in-house, or where the volume of use is not substantial, the Company may consider purchasing extracts from external manufacturers for economic efficiency.
However, herbal extracts procured from external sources must undergo quality analysis and may require additional quality improvement processes before being used in the production process, to ensure conformity with the Company’s quality standards before distribution to customers.
Through this raw material procurement system, the Group is able to effectively control the quality of raw materials, reduce supply chain risks, and support the production of quality and safe products in accordance with international standards.
Raw Material Acquisition (Overall)
The Group places importance on the procurement of quality raw materials that meet appropriate standards, to support the production process of plant-based extracts and health, beauty, and dietary supplement products. The Company selects raw material manufacturers and distributors that are capable and reliable, able to deliver raw materials in compliance with quality specifications, quantities, and delivery timelines.
The Company has established systematic processes for selecting and evaluating raw material manufacturers and distributors by preparing an Approved Vendor List to screen and control vendor quality. The Research and Development Department and the Procurement Department jointly consider vendor qualifications before approval, and regularly evaluate and review vendor performance based on raw material quality, delivery consistency, and the ability to comply with the Company’s requirements.
In addition, the Quality Control Department inspects raw materials upon every receipt from manufacturers or distributors, to ensure that raw materials used in the production process conform to prescribed standards. The Company maintains a policy of sourcing raw materials from at least 2 manufacturers or distributors for key raw materials, in order to reduce the risk of dependence on any single supplier.
The Company’s primary raw materials consist of herbal plants and herbal extracts, which are mostly sourced domestically, particularly from farmer networks and community enterprises that have maintained continuous cooperative relationships with the Company. The Company has operated the “Tan Khun Thai Farm” program to support the development of herbal cultivation among farmers in multiple areas throughout the country, while transferring knowledge in cultivation, harvesting, and processing, to obtain raw materials with quality and active compound content meeting prescribed standards.
This approach enables the Company to control the quality of raw materials from the upstream end of the supply chain, supports the production of quality and safe products in accordance with international standards, and strengthens the sustainability of the business ecosystem and farming communities in the long term.
In 2023–2025, the Company did not purchase raw materials from any single manufacturer or distributor exceeding 30% of total raw material procurement value.
Production Policy (Overall)
The Company plans to invest in machinery under future projects, involving investment in machinery with new technology that upgrades herbal extraction to more efficiently draw out the active compounds of natural raw materials. This will result in extracts with higher concentration and purity that can be used in the pharmaceutical industry, which demands highly concentrated active compounds, as well as in the food industry. The new machinery investment will build upon existing machinery by processing standardized extracts produced by the current machinery through the new machinery’s processes to achieve extracts with higher concentration and purity, for distribution to new customer segments. Therefore, this investment will also result in increased utilization of the existing machinery’s production capacity. In addition, the Group continues to seek growth opportunities and business gaps in new markets on an ongoing basis.
Production capacity is calculated based on 14 working hours per day (8 hours regular working time and 6 hours overtime) and 300 working days per year.
Distributors (Overall)
The Company has 1 manufacturer with cumulative purchases exceeding 10%, which has no direct affiliation with the Company and is merely a business partner with a long trading history and high reliability.
The Company maintains a policy of sourcing raw materials from at least 2 manufacturers or distributors to reduce the risk of dependence on any single manufacturer or distributor.
In 2023–2025, the Company did not purchase raw materials from any single manufacturer or distributor exceeding 30% of total raw material procurement value.
Number of Raw-Material Distributors (Overall)
1
Production Capacity (Overall)
| Item | Unit | Unit (if Other) | Used | Capacity |
|---|---|---|---|---|
| Specialty Natural Products Public Company Limited | Others | kg. | 53.66 | 245,180 |
| Specialty Innovation Company Limited. | Piece | 37.68 | 20,400,000 | |
| Kane Innovation Company Limited. | Piece | 3.1 | 11,880,000 |
Domestic/Overseas Purchase Proportion (Overall)
| Raw Material | Source Country | Value |
|---|---|---|
| Raw materials for production | Thailand | 176,728,542 |
| Raw materials for production | Other | 6,472,234 |
Projects Under Construction
Has Projects Under Construction (Y/N)
Yes
Description
This project is a strategic collaboration between SNPS and an overseas listed company for the research and development of a dietary supplement product incorporating Thai herbal extracts. The objective is to develop the product formulation, scale up production to an industrial level, and obtain registration approval from the Thai Food and Drug Administration (TFDA) for commercial distribution.
Total Projects
1
Total Project Value
7837000.0
Recognized Value
6204000.0
Remaining / Unrecognized Value
1633000.0
Projects
| Project Name | Value | Income % | Est. Years | Est. Months | Est. Completion |
|---|---|---|---|---|---|
| R&D Project | 7,837,000 | 79.16 | 2 | 7 | 2027-09-01 |
Debentures & Bills of Exchange
Has Debentures (Y/N)
No
Convertible Securities
Has Convertible Securities (Y/N)
No

